Comparison of obese and non-obese patients in terms of sharp object injuries: A retrospective evaluation
Yükleniyor...
Dosyalar
Tarih
2020
Dergi Başlığı
Dergi ISSN
Cilt Başlığı
Yayıncı
Erişim Hakkı
info:eu-repo/semantics/openAccess
Özet
Aim: Few studies have evaluated real-world clinical experience with sofosbuvir (SOF) plus ribavirin (RBV) in hepatitis C virus (HCV)
genotypes 2 and 3 infections from Turkey. Thus, this study aimed to investigate the results of sofosbuvir plus ribavirin therapy in
genotype 2 and 3 cases followed in an infectious disease clinic at a university hospital in Hatay, southern Turkey.
Material and Methods: In this single-centre, retrospective, observational study, 58 eligible patients treated with SOF/RBV (400 mg
of SOF plus weight-based RBV) therapy between October 2016 and February 2019 were examined. Forty-three patients who had
completed the duration of treatment and had known virological response status were evaluated for treatment outcomes.
Results: SOF/RBV achieves a sustained virological response (SVR) rate of 96.3% and 100% in the HCV genotype 2 and 3 groups,
respectively, with treatment duration of 12-24 weeks. No patient experienced a virologic breakthrough while only one experienced
virologic relapse after the completion of therapy. The incidence of adverse events was 25.5% (11/43) while the most common
(11.6%) adverse event was ribavirin-related hemolytic anemia.
Conclusion: The current study revealed that the SOF/RBV therapy achieved excellent response rates with a good safety profile in
non-cirrhotic Turkish patients infected with HCV genotype 2 or 3
Açıklama
Anahtar Kelimeler
Kaynak
Annals of Medical Research
WoS Q DeÄŸeri
Scopus Q DeÄŸeri
Cilt
Sayı
Künye
Talih, T., Topal, U., Mutevelli Sozuer, E., Dal, F., & Yakup Akyildiz, H. (2021). Comparison of obese and non-obese patients in terms of sharp object injuries: A retrospective evaluation . Annals of Medical Research
